HKSE · 2096.HK
Simcere Pharmaceutical Group Limited
HK$10.40+HK$0.02 (+0.19%)
Simcere Pharmaceutical Group Limited’s quoted price sits in the lower half of its reported 52-week range, 27.68% below the high.
Loading market information…
HKSE · 2348.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Dawnrays Pharmaceutical (Holdings) Limited’s quoted price is below the reported 52-week low. The range and quote may have different update times.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Dawnrays Pharmaceutical (Holdings) Limited’s forward annual dividend is HK$0.03 per share, paid semi-annual. The forward yield is 3.3% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Dawnrays Pharmaceutical (Holdings) Limited’s next earnings report is currently expected on Mar 19, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Dawnrays Pharmaceutical (Holdings) Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Dawnrays Pharmaceutical (Holdings) Limited operates as an investment holding company, primarily engaged in the creation, production, and global distribution of generic pharmaceutical medicines, with a focus on Mainland China and international markets. Its operations are divided into two main divisions: Intermediates and Bulk Medicines, and Finished Drugs. The company's diverse product portfolio features a range of antibiotics, including pharmaceutical intermediates, bulk active ingredients, powdered formulations for injection, and oral antibiotic preparations. Furthermore, Dawnrays offers specialized medications addressing various bodily systems and conditions, such as those for cardiovascular health, allergies, Hepatitis B Virus (HBV), digestive and urinary issues, antipyretic-analgesic (fever and pain relief), respiratory ailments, and endocrine disorders. These system-specific drugs are dispensed in familiar forms like tablets, capsules, and granules. Founded in 1995, the firm maintains its headquarters in Wan Chai, Hong Kong, and is a subsidiary of Fortune United Group Limited.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2022 | Aug 26, 2022 | HK$0.13 | HK$730.31M-49.33% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$10.40+HK$0.02 (+0.19%)
Simcere Pharmaceutical Group Limited’s quoted price sits in the lower half of its reported 52-week range, 27.68% below the high.
HK$6.93+HK$0.08 (+1.09%)
The United Laboratories International Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 49.49% below the high.
HK$141.00HK$0.00 (0.0%)
Fujian Haixi Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 53.37% below the high.
HK$0.75+HK$0.04 (+4.93%)
Sihuan Pharmaceutical Holdings Group Ltd.’s quoted price sits in the lower half of its reported 52-week range, 58.38% below the high.
HK$0.94-HK$0.01 (-0.53%)
Jacobson Pharma Corporation Limited’s quoted price sits in the lower half of its reported 52-week range, 36.91% below the high.
HK$1.67+HK$0.06 (+3.73%)
JBM (Healthcare) Limited’s quoted price sits in the lower half of its reported 52-week range, 46.3% below the high.
HK$2.02HK$0.00 (0.0%)
Essex Bio-Technology Limited’s quoted price sits in the lower half of its reported 52-week range, 56.57% below the high.
HK$1.00HK$0.00 (0.0%)
Fusen Pharmaceutical Company Limited’s quoted price sits in the lower half of its reported 52-week range, 30.56% below the high.
